Introduction
A n adverse drug event (ADE) refers to any injury occurring at the time a drug is being used, whether or not it is identified as a cause of the injury. [1] [2] [3] An adverse drug reaction (ADR) is a special form of ADE in which a causative relationship can be shown or established and is attributable to the offending/ precipitating medication. [4] [5] [6] ADR causality assessment is used to determine the likelihood that a particular drug caused a suspected ADR. [7] [8] [9] [10] Causality assessment rating is the evaluation of the relationship between drug treatment and the occurrence of an ADE. It is also used to evaluate, check, confirm, and ascertain that the particular treatment is the cause of an observed adverse event or not. [11] [12] [13] There are a number of different methods used to judge causation, including the Naranjo algorithm, the World Health Organization (WHO) causality assessment criteria, and the Venulet algorithm. Each have pros and cons associated with their use and most require some level of expert judgment to apply. [4, 5, 10, 11, [14] [15] [16] The Naranjo algorithm, also known as Naranjo Scale, or Naranjo Nomogram is a questionnaire designed by Naranjo et al. for determining the likelihood of whether an ADR is actually due to the drug rather than the result of other factors. Probability is assigned via a score termed definite, probable, possible, or doubtful. Values obtained from this algorithm is used to verify the validity of conclusions regarding ADRs. Naranjo scores of 9 or 10 indicate that an event was "definitely" an ADR; scores of 5-8 rate the likelihood as "probable;" scores of 1-4 are "possible;" and scores of <1 (that is, zero) are "doubtful." [5, 6, [16] [17] [18] [19] An ADR should not be labeled as "certain" unless the ADR abates with a challenge-dechallenge-rechallenge (CDR) protocol of stopping and restarting the agent in question. The CDR is a medical testing protocol in which a medicine or drug is administered, withdrawn, then re-administered, while being monitored for adverse effects at each stage. [20] [21] [22] [23] The CDR protocol is used when statistical testing is inappropriate due to an idiosyncratic reaction by a specific individual, or a lack of sufficient test subjects and unit of analysis is the individual. During the withdraw phase, the medication is allowed to wash out of the system to determine what effect the medication is having on an individual. CDR is one means of establishing the validity and benefits of medication in treating specific conditions as well as any ADRs. [24] [25] [26] The Food and Drug Administration (FDA) of the United States lists positive dechallenge reactions (an adverse event which disappears on withdrawal of the medication) as well as negative (an adverse event which continues after withdrawal), as well as positive rechallenge (symptoms re-occurring on re-administration) and negative rechallenge (failure of a symptom to re-occur after re-administration). [27, 28] It is one of the standard means of assessing ADRs worldwide. The chronology of the onset of the suspected ADR is important, as another substance or factor may be implicated as a cause; co-prescribed medications and underlying psychiatric conditions may be factors in the ADR. [29] Assigning causality to a specific agent often proves difficult unless the event is found during a clinical study or large databases are used. Both methods have difficulties and can be fraught with error. Even in clinical studies some ADRs may be missed as large numbers of test individuals are required to find out that ADR. Psychiatric ADRs are often missed as they are grouped together in the questionnaires used to assess the population. [10] [11] [12] 30] It is important to recognize when a patient is experiencing an ADR, or the oversight may lead to subsequent prescribing of more drugs to correct the drug-induced disease. However, it may be difficult to distinguish an ADR from an exacerbation of an existing disease or a new medical problem because the clinical picture is so complex. Such challenges test the diagnostic expertise of the best clinicians. However, to recognize an ADR, you must first entertain the possibility of an adverse event. If you don't even look, you won't find them. When a drug reaction is suspected, the clinician should investigate whether that particular drug is known to cause such a reaction, rule out alternative explanations, and establish a temporal link between the onset of the reaction and drug administration. When empirical methods fail or produce cloudy causation results, the more formal process of using a probability assessment tool, such as the Naranjo algorithm scale, will often produce clearer results. The bottom line of recognizing ADRs is this: whenever a patient experiences what looks like an exacerbation of an existing condition, or when a patient develops what seems like a new medical problem while being treated for something else, the possibility of an ADR must be added to the differential diagnosis. It may just be the drug! Despite the extensive study and attention given to ADRs, they still represent a clinically significant problem and with the high burden. [29, 30] Pharmaceutical treatments sometimes addition, the mortality rate and case fatality rate for ADRs were significantly high among these adult medical inpatients.
Keywords: Adverse drug reaction-associated mortality rate, adverse drug reaction-case fatality rate, adult medical inpatients, causality assessment rating, Naranjo algorithm, World Health Organization causality rating criteria result in ADEs either due to inherent ADRs or from inappropriate medicine use or medication errors. [25, 27, 30] Many countries have official bodies that monitor drug safety and reactions. At the international level, the WHO runs the Uppsala Monitoring Centre, and the European Union runs the European Medicines Agency. In the United States, the FDA is responsible for monitoring postmarketing studies. In Canada, the Marketed Health Products Directorate of Health Canada is responsible for the surveillance of marketed health products. In Australia, the Therapeutic Goods Administration (TGA) conducts postmarket monitoring of therapeutic products. In the United Kingdom (UK) the Yellow Card Scheme was established in 1963. [30] [31] [32] [33] While in Nigeria, the National Agency for Food Drug Administration and Control (NAFDAC) monitor such similar health-related safety activities concerning food and drug products. [34, 35] In developing countries including Nigeria, there is minimal information on the in-hospital causality assessment of ADRs and the culprit medications. [36] [37] [38] This study was designed to evaluate the causality assessment rating, mortality rate, and case fatality rate for ADRs among adult medical inpatients at the University of Benin Teaching Hospital (UBTH), Benin City, Edo State, Nigeria with the goal of preventing them and improving their treatment outcome.
Methods
This was a descriptive, prospective study with serial entry points for the patients admitted into the internal medicine wards of UBTH, Benin City, Edo State, South-South Nigeria over a 9-month period from December 2013 to August 2014. They were all adult medical patients whose ages were >17 years and were fulfilling the inclusion criteria for recruitment, evaluation and followed up. Medications prescribed for the admitted patients were supplied by the hospital pharmacy or however, they may occasionally be required to purchase some medications from retail outlets outside the hospital when these drugs are not available in hospital pharmacy. Patients are generally admitted through the accident and emergency unit where they are reviewed by various cadres of medical doctors until they are transferred to the wards under unit consultants. Some patients are admitted directly from the outpatient clinics into the wards, while a few may be transferred in from other nonmedical wards. The patients are then reviewed daily in the various units and managed till discharge.
The inclusion criteria for evaluation were all the patients admitted to the medical wards after commencing the study provided they granted their informed consents to participate in the study. The exclusion criteria include: Those patients already on admission before commencing the study, those patients admitted from other wards after initial management for nonmedical condition(s), those patients diagnosed and subsequently managed for nonmedical condition(s) after initial medical diagnosis and management, and finally, those patients who did not grant their informed consents to participate in the study.
Information collected about all the recruited patients were obtained and entered into a data collection form modified from the WHO-International Network for the Rational Use of Drugs prescribing indicator form. [3] Patients were evaluated with respect to medications used on days 0 (admission day), 1, 3, 7, 10, 14, 21, and weekly thereafter till the day of discharge or death. An encounter was regarded as a patient studied on admission on such specified days. An initial sociodemographic data stating age, sex, religion, occupation among others were obtained at admission. Thereafter, the records of all prescribed medications including the dates, route, doses, and frequencies were all noted for these inpatients during admission. The reviews and changes made in patients' medications between the days of evaluation were also noted to enable the estimation of number of drugs taken during admission.
Information concerning ADR occurrence and its nature was sought from attending physicians, patients, their relatives, and nursing staff. Charts and case notes were screened for records of ADRs. Clinical evaluation and assessment of laboratory results were also carried out. Repeated admission of the same patient was regarded as two separate admissions when separated by an interval of at least 1 month, otherwise such admission was considered as a single admission and the interval excluded from the duration of hospital stay. [16] The definition of ADRs used in the study was that of WHO: "any noxious and unintended response to a drug that occurs at doses used in humans for the prophylaxis, diagnosis or therapy of disease." [3] Using severity grading assessment, ADRs were classified as mild (laboratory abnormality or symptoms not requiring treatment), moderate (laboratory abnormality or symptoms requiring treatment/admission to hospital or resulting in nonpermanent disability), severe (laboratory abnormality or symptoms that were life threatening or resulted in permanent disability), and fatal (any ADR that resulted in patient's death regardless and irrespective of the initial severity grading assessment). [13, 14] The causality assessment rating for ADRs was evaluated using the Naranjo algorithm, [16] as well as the WHO causality rating criteria, [15] while the ADRs were classified according to their severity grading assessment [4, 5, 10] and the System/ Organ Classification. [11] The template outline for the Naranjo algorithm [16] and the WHO causality rating criteria [15] are represented in Table 1a [16] Table 1b: The WHO causality rating criteria for adverse drug reaction assessment [15] Chicago, Illinois, United States of America). Results were expressed as mean ± standard deviation or using frequency and percentage values where necessary. The t-test and Chi-squared test were used to compare means and proportions, respectively. The level of statistical significance was set at value of P < 0.05.
Ethical clearance was obtained from the UBTH Ethical Research Committee before commencing this study. The Ethical Clearance/Protocol Research Number issued for the study was ADM/E.22 A/VOL. VII/104. In addition, a verbal informed consent was obtained from each of the patients whose medical records were used while the medical records for those who did not grant their informed consent were excluded from the study. Consent was sought from the patient's relative where the patient had impaired level of consciousness. Participants' confidentiality were respected and maintained by ensuring that no unauthorized person had access to the information on the data information sheets, that no information can be traced to the subjects (as coding system was used for the data information sheets instead of writing the patients' names on them) and no unauthorized use of information was made.
Results
A total of 507 admitted patients were evaluated during this study. Regarding sex distribution, 269 (53.1%) were male while 238 (46.9%) were female. The mean age for all patients was 48.9 ± 17.8 years (median of 46 years; range of 17 years to 89 years). Although the mean age for females (49.5 ± 17.7 years) was older than that of the males (48.3 ± 17.9 years), the difference was not statistically significant (t = −0.771, df = 505, P = 0.44). Table 2a shows the age and sex distribution of the patients. Table 2a also reveals that those patients under 45 years of age were the most predominant with a frequency of 236 (46.5%) patients, followed by those within the age group of 45-64 years with a frequency of 146 (28.8%) patients. While the elderly age groups (65 years and above) constitute 125 (24.7%) of the admitted patients.
Furthermore, Table 2b shows the details of the medications causing ADRs. The drugs causing the most frequent ADRs were insulin in 14 (27.5%), nonsteroidal anti-inflammatory drugs in 10 (19.6%), antihypertensives in 8 (15.7%), and antimalarials in 5 (9.8%). In addition, herbal medications and antibacterials caused ADRs in 4 (7.8%) and 3 (5.9%) of patients, respectively. These patients taking herbal medications were admitted solely because they have been taking unknown active ingredient(s) containing herbal concoctions at home before their hospital presentation, which was the cause of their adverse medication events (ADR-out) that warrant/necessitate their admission into the adult medical ward for in-patient care. The other medications involved in ADRs are shown in Table 2b . In addition, four fatal ADRs were observed during the study; in which herbal medications caused two deaths, sulfadoxine/pyrimethamine combination (maloxine ® ) caused one death, and iron dextran caused one death.
In this study, the causality assessment rating for the observed ADRs was evaluated using both the WHO causality rating and the Naranjo algorithm as shown in Table 3a . Using the WHO causality rating, certain cases were 10 (19.6%), probable cases were 17 (33.3%), and possible cases were 24 (47.1%). Using the Naranjo algorithm, definite cases were 9 (17.6%), probable cases were 19 (37.3%), and possible cases were 23 (45.1%). Moreover, Table 3b shows that the number of patients admitted solely because of ADRs (ADR-out) was 18 patients, which accounts for 3.6% of admissions, while those that experienced ADRs during admission (ADR-in) were 33 (6.5%) patients. The total number of patients who had ADRs was 51 patients, giving an ADR prevalence of 10.1%. The incidence of ADRs was 6.5% in this study. The case fatality rate for ADRs was 7.8% (4/51), whereas the ADR-associated mortality rate was 0.8% (4/507). Table 4a shows the summary for the duration of hospital stay by different categories of patients. The mean duration of stay by all patients was 11.9 ± 11.3 days (median of 9 days). Females had a mean duration stay of 12.9 ± 12.3 days (median of 10 days) and stayed significantly longer than males who stayed a mean duration of 10.9 ± 10.2 days with a median of 7 days (t = −1.985, df = 505, P = 0.048). The young age group (that is those <45 years old), stayed a mean duration of 11.3 ± 9.3 days (median of 9 days), while the middle age group had a mean duration stay of 11.7 ± 9.7 (median of 10 days). While the elderly age group (65 years and above) had a mean duration stay of 13.0 ± 15.7 (median of 8 days) appeared to have stayed longer than patients <65 years of age (that is, the young and middle age groups). However, this was not found to be statistically significant (t = −1.299, df = 505, P = 0.195).
Patients admitted solely because of ADRs (ADR-out) had a significantly shorter duration of stay with a mean duration stay of 6.1 ± 3.7 days (median duration stay of 7 days) when compared to those without ADRs whose mean duration of stay was 11.6 ± 11.0 days (median duration stay of 8 days), and this was found to be statistically significant (t = 2.110, df = 472, P = 0.035). Those patients who developed ADRs during admission (ADR-in) had a mean duration of stay of 18.3 ± 14.8 (median of 15 days).
This was significantly longer than the duration of stay for patients without ADRs (t = −3.398, df = 487, P = 0.001) and also significantly longer than the duration for those who were admitted solely because of ADRs (t = 3.432, df = 49, P = 0.001). In addition, Table 4b reveals the statistical evaluations of some known risk factors for ADRs, taking into consideration their gender, age, number of medications used and number of comorbidities. Gender was not found to be a statistically significant risk factor for ADRs in this study ( 2 = 0.371, P = 0.542). Age was found to be a statistically significant risk factor as the elderly age group (age ≥65 years) were more at risk compared to those patients <65 years ( 2 = 10.152, P = 0.001).
Number of medications used was also a significant risk factor for developing ADRs ( 2 = 13.174, P = 0.018).
Number of comorbidities was also found to be strongly associated with ADRs ( 2 = 21.962, P < 0.001). This is summarized in Table 4b . The association of ADRs with patients' age group or the number of medications being used by the patients or number of individual patient's comorbidities was estimated by excluding patients who were admitted for ADR (that means, patients who developed ADRs before admission [ADR-out]). Figure 1 shows the frequency distribution pattern for patients experiencing ADRs versus their precipitant culprit drugs. Insulin caused ADRs in the most number of patients 14 (27.5%). Nonsteroidal anti-inflammatory drugs, NSAIDs, was next in the frequency of causation in 10 (19.6%), followed by antihypertensives in 8 (15.7%). Antimalarials, herbal medicines, and antibacterials caused ADRs in 5 (9.8%), 4 (7.8%), and ADR parameter Value ADR-out* 18 (3.6%) ADR-in* (incidence) 33 (6.5%) Total ADR (prevalence) 51 (10.1%) ADR case fatality rate 7.8% (4/51) ADR-associated overall mortality rate 0.8% (4/507) *ADR-out: Patients admitted solely because of adverse drug reactions, *ADR-in: Patients that developed adverse drug reactions during admission. ADR: Adverse drug reaction in 89 (17.6%) patients, and the cardiovascular system in 40 (7.8%) patients. The endocrine, respiratory, and renal systems were equally affected in 20 (3.9%) patients each. In this study, it was observed that ADRs often affected multiple body systems within a patient.
Finally, Table 5 revealed that most of the ADRs were mild and moderate in 21 (41.2%) cases and 24 (47.1%) cases, respectively. Severe ADRs occurred in 2 (3.9%) cases, whereas 4 (7.8%) cases were fatal ADRs.
Discussion
This study was designed to evaluate the causality assessment rating, mortality rate, and case fatality rate for ADRs among adult medical inpatients in a Nigerian University Tertiary Healthcare setting with the goal of preventing them and improving their treatment outcome. The two methods used to ascertain causality rating for ADRs caused by a particular suspected drug; both the WHO causality rating and Naranjo algorithms, showed similar causality ratings, which strengthening the ascribed ADR causality rating. Taking into consideration the WHO causality rating; certain cases were 10 (19.6%), probable cases were 17 (33.3%), and possible cases were 24 (47.1%). While using the Naranjo algorithm, definite cases were 9 (17.6%), probable cases were 19 (37.3%), and possible cases were 23 (45.1%). The ADR-associated mortality rate of 0.8% was somewhat between values obtained in a U. K study (0.15%) and that obtained in a Swiss study (1.4%). The lower rate observed in the UK study can be attributed to the fact Figure 1 .
The systems/organs involved in ADRs are shown in Figure 2 . The most frequently involved body system was the central nervous system (neurological) in 169 (33.3%) patients. This was followed by the gastrointestinal system in 110 (21.6%) patients, the skin (dermatological) that the study looked at ADRs causing admissions only. The Swiss study showed a higher mortality, but also looked at both ADRs causing admission and those occurring during admission. The ADR case fatality rate in this present study stood at 7.8%. [6, 11] ADRs occurring during admission (incidence) was observed in 6.5% of admitted patients, while 3.6% of the patients were admitted due to an ADR. The prevalence of 10.1% was similar to the ADR prevalence obtained in some European studies ranging from 6.6% to 11%. [6, 11, 17] A meta-analysis in the United States (US) by Lazarou et al. obtained an incidence of 6.7% for serious ADR among in-patients. The incidence and prevalence values observed in this study thus appears to be consistent with the values in previous studies done in Switzerland, France, UK, and US. [9, 11, 17] The most commonly affected system by ADRs in this present study was the central nervous system, probably because two out of the first three topmost implicated classes of medications causing ADRs manifest with symptoms referable to the central nervous system. For example, insulin leads to impair consciousness due to hypoglycaemia, while antihypertensives manifest mainly with postural dizziness and headache due to postural hypotension and increased intracranial pressure, respectively. The next most common system involved was the gastrointestinal system, and this may be related to the fact that NSAIDs which constituted the second most common class of medications involved in ADRs usually manifest with problems referable to the gastrointestinal system. In fact, the systems largely affected followed the pattern of medications causing ADRs. Fattinger et al. found the gastrointestinal and the hematological systems as the first and second most commonly affected, respectively, among inpatients. The pattern of morbidity and thus medication used differ in both settings; therefore, the pattern of ADRs will be different. Mild and moderate ADR cases were far more frequent (41.2% and 47.1%, respectively) when compared to severe and fatal ADR cases. This pattern is similar to findings in other studies. [13, 14] Patients experiencing ADR during hospitalization (ADR-in) stayed significantly longer than those without ADRs (median stay of 15 days versus 8 days, respectively). ADR have been found to prolong duration of hospital stay in several studies. [6] [7] [8] [9] The median length of stay obtained for patients with ADR-in and those without ADR (15 days and 8 days, respectively) is similar to results obtained in an in-patient study by Davies et al. (14.5 days and 8 days, respectively). Patients admitted solely because of ADRs (ADR-out), had a statistically significant shorter duration of hospital stay (median of 7 days) than those patients without ADR that stayed a median duration of 8 days and also much shorter than those patients that developed ADR during hospitalization (median duration of 15 days). The finding of shorter duration of hospital stay for patients with ADR causing admission (occurring outside the hospital) compared to those without ADR and those with ADR occurring during admission has been noted in a French study. This shorter duration of hospital stay is related to the fact that there is a shorter diagnostic time for ADRs, in effect a shorter time was spent looking for the cause of morbidity since this was obvious from initial clinical evaluation, especially as most of the ADRs were mild (41.2%) or moderate (47.1%). Furthermore their clinical management was essentially observational care and measures such as stopping or adjusting drug dosage. [17] However, a few of the patients required more intense treatment with prolonged stay.
Gender was not found to be a statistically significant risk factor associated with ADR in this study. This finding here differs from what has been observed in other several studies. [6, 11, 17, 18] The association of gender and ADRs like other aspects of ADRs is not well characterized among Nigerians and may differ. Some other known risk factors for ADR were, however, found to be significantly associated with ADRs in this study. Precisely, the elderly age group (≥65 years), presence of polypharmacy (taking more than five different pharmacologically active medications by a particular patient at the same time), and the presence of multiple comorbidities in a particular patient are clinically proven and significant risk factors found to be associated with and predisposed adult medical inpatients to ADRs in this study.
The limitation and strength of this study was that it considered only consented adult medical inpatients; while unconsented adult medical inpatients, pediatric unit patients and adult surgical unit patients were completely excluded from the study. Although the number of unconsented adult medical in-patients excluded from this study was statistically insignificant (about 8 patients). Finally, all the observed results are completely and exclusively applicable to only adult medical in-patients in clinical practice setting.
Conclusion
In this study, the two methods used to ascertain causality rate for ADRs caused by a suspected drug; both the WHO causality rating and Naranjo algorithms, showed similar causality ratings, which strengthening the ascribed ADR causality rating. In addition, the mortality rate and case fatality rate for ADRs were significantly high among these adult medical in-patients. Mild and moderate ADR cases were far more frequent (41.2% and 47.1%, respectively) when compared to severe and fatal ADR cases; this pattern of severity is similar to findings in other studies. This information is useful for health-care planning, management, budgeting, policy formulation, and development of treatment protocols to enable appropriate and optimal patient care.
